Introduction:
The biologics industry in Canada is experiencing significant growth, driven by increasing demand for innovative treatments and advancements in biotechnology. With a focus on importing top-quality biologics, Canada is becoming a key player in the global pharmaceutical market. In 2025, the biologics market in Canada was valued at $5.6 billion, with a projected growth rate of 8% annually.
Top 10 Biologics Importers in Canada 2026:
1. Roche Canada
Roche Canada is a leading importer of biologics in Canada, with a market share of 15%. The company specializes in oncology, immunology, and infectious diseases treatments, contributing to Canada’s growing healthcare landscape.
2. Pfizer Canada
Pfizer Canada is another major player in the biologics import market, holding a 12% market share. The company’s diverse portfolio of biologics includes vaccines, biosimilars, and innovative therapies, catering to a wide range of healthcare needs in Canada.
3. AbbVie Canada
AbbVie Canada is known for its top-selling biologics in Canada, with a market share of 10%. The company focuses on treatments for autoimmune diseases, oncology, and dermatology, providing essential healthcare solutions to Canadian patients.
4. Amgen Canada
Amgen Canada is a key importer of biologics, holding a 9% market share in Canada. The company’s biologics portfolio includes innovative therapies for cancer, bone health, and cardiovascular diseases, contributing to advancements in Canadian healthcare.
5. Novartis Canada
Novartis Canada is a prominent importer of biologics, with an 8% market share in Canada. The company’s focus on research and development has led to the introduction of cutting-edge biologics for various therapeutic areas, enhancing patient care in Canada.
6. Merck Canada
Merck Canada is a leading importer of biologics, holding a 7% market share in Canada. The company’s biologics portfolio includes treatments for diabetes, cardiovascular diseases, and infectious diseases, addressing critical healthcare needs in the country.
7. Sanofi Canada
Sanofi Canada is a major player in the biologics import market, with a 6% market share in Canada. The company’s biologics offerings span across multiple therapeutic areas, including rare diseases, oncology, and neurology, contributing to improved patient outcomes in Canada.
8. Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is a significant importer of biologics, holding a 5% market share in Canada. The company’s focus on immunotherapy and oncology treatments has positioned it as a key player in advancing cancer care in Canada.
9. Johnson & Johnson Canada
Johnson & Johnson Canada is a leading importer of biologics, with a 4% market share in Canada. The company’s biologics portfolio includes treatments for autoimmune diseases, infectious diseases, and neuroscience, playing a vital role in Canadian healthcare.
10. AstraZeneca Canada
AstraZeneca Canada is a key importer of biologics, holding a 3% market share in Canada. The company’s biologics offerings focus on respiratory, cardiovascular, and oncology treatments, contributing to improved patient outcomes and quality of life in Canada.
Insights:
The biologics import market in Canada is expected to continue growing steadily, driven by increasing demand for innovative therapies and advancements in biotechnology. By 2026, the market is projected to reach $7.2 billion, with a compound annual growth rate of 9%. With a strong emphasis on quality and patient care, Canada is set to remain a top destination for biologics importers, offering opportunities for growth and collaboration in the pharmaceutical industry. As the healthcare landscape evolves, importers will need to focus on diversifying their portfolios and expanding their presence in key therapeutic areas to meet the changing needs of Canadian patients.
Related Analysis: View Previous Industry Report
